Skip to main content
CORT
NASDAQ Life Sciences

Corcept Q2 Revenue Jumps 32% to $256M, Raises 2026 Guidance to $1.1–$1.2B on Lifyorli Launch

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$110
Mkt Cap
$9.978B
52W Low
$28.66
52W High
$97.63
52W Position info
284% above low
Off High info
at 52W high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

CORT has more than doubled off its 52-week low of $28.66.

Summary

Corcept delivered a strong Q2 with revenue of $256.1M, up 32% year-over-year, driven by the launch of oncology drug Lifyorli which contributed $47.6M in its first quarter. The Cushing's syndrome franchise also hit record new prescriptions. Management raised full-year 2026 revenue guidance to $1.1–$1.2 billion, signaling confidence in sustained momentum. This follows a mixed Q1 where revenue missed estimates and the ALS trial failed, but the relacorilant NDA resubmission in June and DOJ declining to intervene in a qui tam suit have since shifted sentiment. The PDUFA date for relacorilant in Cushing's is December 17, 2026, with an EMA decision in ovarian cancer also expected this year. Multiple oncology and MASH trial readouts are due by year-end, providing a rich catalyst calendar.

Updates

  1. · SEC 10-Q — CEO and CAO adopted 10b5-1 trading plans; cash and marketable securities totaled $544.6M at June 30, 2026.

At the time of this announcement, CORT was trading at $110.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $28.66 to $97.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

CORT - Latest Insights

CORT
Nov 03, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $78.50
Real-time Price: $80.60 info
Change: +$2.10 (+3%) info
Market Cap: $8.857B info
CORT
Nov 03, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $81.93
Real-time Price: $80.60 info
Change: -$1.33 (-2%) info
Market Cap: $8.857B info
CORT
Oct 26, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $86.01
Real-time Price: $80.60 info
Change: -$5.41 (-6%) info
Market Cap: $8.857B info
CORT
Oct 20, 2026, 4:00 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $116.51
Real-time Price: $80.60 info
Change: -$35.91 (-31%) info
Market Cap: $8.857B info
CORT
Sep 18, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $114.90
Real-time Price: $80.60 info
Change: -$34.30 (-30%) info
Market Cap: $8.857B info